Latest news with #Therma
Daily Mail
3 days ago
- Health
- Daily Mail
The underrated and wondrously wild Greek island that's been named best to visit in 2025
A gorgeous Greek island that's 'well beyond the usual tourist radar' has been named as one of the best of the country's islands to visit in 2025. According to Lonely Planet, Ikaria is one of the best Greek islands to add to your bucket list. While the island isn't a leading tourist destination, it has been globally recognised for its long-living residents. Ikaria is one of the world's five designated 'Blue Zones', places where people are much more likely to live to 100. But why is it one of 2025's best Greek islands to visit? Lonely Planet reveals: 'It takes effort to get to Ikaria, a wondrously wild island in the eastern Aegean, but those who make it this far too rewarded. 'Ruggedly mountainous, gorge-riven, thickly forested and well beyond the usual tourist radar, this island has its own look and culture.' According to Homeric legend, Dionysus, the god of wine and theatre, was born on Ikaria. At Therma, a spa village on the island, tourists can unwind in Ikaria's hot mineral springs which are thought to soothe arthritis and rheumatism The island is heavily tied to Greek myth and even earns its name from Icarus, the man who flew too close to the sun. Lonely Planet recommends hiring a car to explore the island to make your holiday 'feel like a proper adventure'. The travel guide suggests heading to Seychelles Beach, known for its 'dazzling azure waters'. A picturesque cove, Seychelles Beach has bright pebbles and is backed by rock formations. At Therma, a spa village on the island, tourists can unwind in Ikaria's hot mineral springs which are thought to soothe arthritis and rheumatism. Those looking to emulate the islanders' healthy lifestyle can head into the hills to see the giant rock houses where locals used to hide from pirate attacks. 'These stiff climbs - along with a herb-rich diet - are part of what contribute to the island's extraordinarily high number of centenarians,' reveals Lonely Planet. While Lonely Planet recommends taking a ferry from Kos to Ikaria, it can also be reached by plane from Athens. Those looking to emulate the islanders' healthy lifestyle can head into the hills to see the giant rock houses where locals used to hide from pirate attacks The travel guide suggests that tourists spend two weeks on Ikaria to let the island 'truly work its magic'. And Greece is also home to Europe's best beach, according to a new ranking. Port Glarokavos Lagoon Beach took the crown in a ranking put together by judges at European Beach Destinations. The beautiful Greek beach is located on the country's northern Kassandra Peninsula.
Yahoo
16-04-2025
- Business
- Yahoo
Therma Bright Reviews Manufacturing Strategy in Light of US Tariff Changes
Toronto, Ontario--(Newsfile Corp. - April 16, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to provide an update to address the potential impact of recent and evolving US tariff policies on our current manufacturing operations of Venowave in China, which serves the US market. The Company is actively reviewing the implications of recent tariff changes imposed by the US on goods manufactured in foreign countries, particularly China. These tariffs have the potential to significantly increase the cost of our products sold in the US market. In response, Therma has initiated a comprehensive review of all available manufacturing options to ensure the long-term competitiveness and stability of our supply chain. Therma is reviewing various manufacturing options which includes a thorough analysis of onshoring and establishing manufacturing capabilities within North America (Canada, USA, or Mexico). The Company is also considering a hybrid approach; combining manufacturing of Venowave or component parts in China with onshoring in North America. In the case of continued full manufacturing of Venowave in China the option will be evaluated in conjunction with strategies to mitigate tariff costs, including potential absorption of some or all tariff expenses if financially feasible in the current dynamic environment. The Company's decision-making process will extend beyond pure cost considerations and will encompass critical factors such as: Supply chain resilience: assessing the stability and reliability of different manufacturing locations and potential risks. Lead Times: evaluating the impact on production and delivery timelines. Quality Control: ensuring consistent product quality across different manufacturing environments. Intellectual Property Protection: considering the risks associated with different manufacturing locations. Logistics and Transportation: analysing the efficiency and cost of moving goods from various manufacturing sites to the US market. Market Access and Geopolitical Stability: evaluating the long-term implications of manufacturing locations on market access and geopolitical risks. Therma Bright recognizes that the current tariff landscape is subject to change. Our analysis will consider various potential scenarios and their impact on our business. It is important to emphasize that no final decision regarding our future manufacturing strategy has been made at this time. The Company is committed to keeping our shareholders informed. We will provide a further update once our comprehensive review is complete and a definitive course of action has been determined. We appreciate our shareholders' understanding as we navigate this evolving situation and work to ensure the long-term success of the Company. Therma Bright would also like to announce that it continues to work with national distributors to expand the market presence for Venowave with further updates in the near future. The Venowave VW5, which qualifies for Medicare and Medicaid HCPCS code reimbursement under 10 medical indications, is a compact, battery-operated peristaltic pump designed to enhance vascular and lymphatic flow in the lower limbs. When strapped below the knee, the device generates a wave-form motion that compresses the calf, promoting upward displacement of venous and lymphatic fluid. Powered by a single rechargeable 1.5V NiMH AA battery, the FDA-designated Durable Medical Equipment (DME) device allows users to receive treatment while staying active. The Venowave VW5 is built for durability and supports repeated use across multiple patients. About Therma Bright Bright develops and partners on cutting-edge diagnostic and medical device technologies that address key healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: Therma Bright Fia, CEOrfia@ Follow us X FORWARD-LOOKING STATEMENTS Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as manufacturing and future sales of Venowave and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. To view the source version of this press release, please visit
